Journal article
Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with All HCV genotypes
S Naggie, NI Rallon, JM Benito, J Morello, S Rodriguez-Novoa, PJ Clark, AJ Thompson, KV Shianna, E Vispo, JG McHutchison, DB Goldstein, V Soriano
Journal of Infectious Diseases | Published : 2012
Abstract
Background. A recent genome-wide association study reported a strong association with a single-nucleotide polymorphism (SNP) in the inosine triphosphate (ITPA) gene and hemolytic anemia in patients infected with hepatitis C virus (HCV) receiving pegylated interferon and ribavirin. We investigate these polymorphisms in a cohort of human immunodeficiency virus (HIV)/HCV-coinfected patients. Methods. DNA was available for 161 patients with validated outcomes. We analyzed the association between the variants and week 4 hemoglobin reduction. Anemia over the course of therapy, ribavirin (RBV) dose reduction, serum RBV level, and rapid virological response (RVR) and sustained virological response (..
View full abstractGrants
Awarded by National Institute of Allergy and Infectious Diseases
Funding Acknowledgements
This work was supported by the National Institutes of Allergy and Infectious Diseases, 1K23-A1096913-01 (S.N.).